Health TrialsbyHealthPanel

Searching Biomarkers of Acute Intestinal Ischemic Injuries

ConditionAcute Mesenteric Ischemia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

The aim of the SURVIBIO study is to characterize accurate biomarkers for acute mesenteric ischemia, in particular at early stages.

In the study, the development of biomarkers will be based on the analysis of human biological samples from patients and controls that will be conserved in a biological library. Samples will be analysed in the Laboratory for Vascular Translational Sciences (LVTS, Inserm U1148), in the Department of Biochemistry (Pr Puy, Dr Peoc'h), in Paris V university , in Imperial College of London (Pr Dumas), in Jacques Monod Institute and in Maastricht University Medical Center . The candidate markers will be determined according to an a priori method (form markers already described in the literature) and with no a priori strategy using -omics methods.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

age> 18 years

Acute abdominal pain requiring an injected abdominal injected CT scan, at best at non-injected / early arterial / portal time

Admitted or attended in Beaujon and / or Bichat hospitals

Patient covered by a social security scheme

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • blood sampling

    Biological/Vaccine

    Two tubes of 5ml of blood will be collected for Serum collection, 3 tubes of 5 ml of blood taken for plasma collection and 2 tubes of 7 ml of blood taken for DNA collection

Treatment groups

556 Participants
are divided into 2 treatment groups
Group A: PatientExperimental treatment 1 intervention
Group B: witnessExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

observation of clinical-bio-scanographic pain related to a splanchnic-mesenteric, occlusive or non-occlusive vascular insufficiency, to abdominal CT angiography, in the absence of another identifiable cause

Time frame
2 years

Secondary outcomes

1

mortality and causes

Time frame
2 years
2

Intestinal resection ratio

Time frame
2 years
3

acute intestinal ischemic injury relapse ratio

Time frame
2 years
4

short gut syndrome features

Time frame
2 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assistance Publique - Hôpitaux de Paris

Lead sponsor

Source ClinicalTrials.gov
Apply now